Suppr超能文献

乳腺髓样癌、非典型髓样癌及高级别浸润性导管癌中HER-2/neu、p53、MIB1以及雌激素受体/孕激素受体的差异扩增与过表达。

Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.

作者信息

Xu Ruliang, Feiner Helen, Li Peng, Yee Herman, Inghirami Giorgio, Delgado Yara, Perle Mary Ann

机构信息

Department of Pathology, Mount Sinai School of Medicine of New York University, New York, NY, USA.

出版信息

Arch Pathol Lab Med. 2003 Nov;127(11):1458-64. doi: 10.5858/2003-127-1458-DAAOON.

Abstract

CONTEXT

Medullary carcinoma (MC) is a special type of breast cancer that has a better prognosis than atypical medullary carcinoma (AMC) and high-grade invasive ductal carcinoma (HGIDC) with prominent lymphocytic infiltrates. What accounts for the different clinical courses of these carcinomas, despite their similar histology, is unknown. To address this issue, we performed a comparative study of amplification and overexpression of HER-2/neu and expression of several other important biochemical markers (p53, MIB1, and estrogen receptor [ER]/progesterone receptor [PR]) in these 3 cancer groups.

OBJECTIVE

To evaluate HER-2/neu, p53, MIB1, and ER/PR as markers in the differential diagnosis of MC, AMC, and HGIDC.Design.-Nine cases of MC, 13 cases of AMC, and 16 cases of HGIDC with prominent lymphocytic infiltrates were identified according to strict histologic criteria. All tests were performed on formalin-fixed, paraffin-embedded archival tissues. HER-2/neu gene amplification was examined by fluorescence in situ hybridization using PathVysion HER-2 DNA probes. Expression of HER-2/neu, p53, MIB1, and ER/PR was detected by immunohistochemistry. chi2 and Student t tests were applied for statistical analyses.

RESULTS

None of 9 cases of MC examined had either amplification or overexpression of HER-2/neu (0%). In contrast, HER-2/neu amplification was observed in AMC (46%, P <.025) and HGIDC (56%, P <.005). All 3 categories of tumors had similar percentages of expression of p53 (78% of MC, 77% of AMC, and 69% of HGIDC) and MIB1 (89% of MC, 92% of AMC, and 94% of HGIDC). Immunostaining for ER/PR was rarely positive in either MC or AMC, and there were no significant differences of expression of ER/PR between these 2 lesions (P >.05). However, the expression rate of ER/PR (31%/44%) in HGIDC is higher than in both MC (P =.05) and AMC (P =.01).

CONCLUSIONS

Medullary carcinoma of breast is distinct from AMC and HGIDC with prominent lymphocytic infiltrates in amplification and overexpression of HER-2/neu. This difference may account for its different clinical and biological behavior, and may potentially aid in diagnosis and management of these groups of patients.

摘要

背景

髓样癌(MC)是一种特殊类型的乳腺癌,其预后优于非典型髓样癌(AMC)和伴有显著淋巴细胞浸润的高级别浸润性导管癌(HGIDC)。尽管这些癌的组织学相似,但其不同临床病程的原因尚不清楚。为解决这一问题,我们对这3组癌症中HER-2/neu的扩增和过表达以及其他几种重要生化标志物(p53、MIB1和雌激素受体[ER]/孕激素受体[PR])的表达进行了比较研究。

目的

评估HER-2/neu、p53、MIB1和ER/PR作为MC、AMC和HGIDC鉴别诊断标志物的价值。

设计

根据严格的组织学标准,确定9例MC、13例AMC和16例伴有显著淋巴细胞浸润的HGIDC。所有检测均在福尔马林固定、石蜡包埋的存档组织上进行。使用PathVysion HER-2 DNA探针通过荧光原位杂交检测HER-2/neu基因扩增。通过免疫组织化学检测HER-2/neu、p53、MIB1和ER/PR的表达。采用卡方检验和学生t检验进行统计分析。

结果

9例接受检测的MC均未出现HER-2/neu的扩增或过表达(0%)。相比之下,AMC(46%,P<.025)和HGIDC(56%,P<.005)中观察到HER-2/neu扩增。所有3类肿瘤的p53(MC为78%,AMC为77%,HGIDC为69%)和MIB1(MC为89%,AMC为92%,HGIDC为94%)表达百分比相似。MC或AMC中ER/PR免疫染色很少呈阳性,且这2种病变之间ER/PR的表达无显著差异(P>.05)。然而,HGIDC中ER/PR的表达率(31%/44%)高于MC(P =.05)和AMC(P =.01)。

结论

乳腺髓样癌在HER-2/neu的扩增和过表达方面与伴有显著淋巴细胞浸润的AMC和HGIDC不同。这种差异可能解释其不同的临床和生物学行为,并可能有助于这些患者群体的诊断和管理。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验